Patrick Mahaffy, Clovis CEO (Kathryn Scott Osler/The Denver Post via Getty Images)

That big R&D PARP win Clo­vis CEO Ma­haffy tout­ed a few weeks ago? The FDA is­n't buy­ing it

Once again, you’ll have to go to the fine print in an SEC fil­ing to find the bad news that has been steadi­ly killing Clo­vis On­col­o­gy’s share price for years.

Just weeks af­ter Clo­vis did its lev­el best to trum­pet a big win for its stunt­ed cash calf Rubra­ca in a Phase III ovar­i­an can­cer study, you can go to the SEC site to see why its bruised and bat­tered stock price is get­ting pum­meled one more time.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.